Skip to main content

Newly Diagnosed

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
1 program
1
Olaparib 300mg tabletsPhase 31 trial
Active Trials
NCT01844986Active Not Recruiting450Est. Aug 2028
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Olaparib 300mg tabletsPhase 3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
MSDOlaparib 300mg tablets

Clinical Trials (1)

Total enrollment: 450 patients across 1 trials

NCT01844986MSDOlaparib 300mg tablets

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Start: Aug 2013Est. completion: Aug 2028450 patients
Phase 3Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.